News

ProKidney Highlights 2024 Achievements and Financial Results

ProKidney Highlights 2024 Achievements and Financial Results

Overview of ProKidney's Financial Success

ProKidney Corp. (Nasdaq: PROK) has charted an impressive course in 2024, marked by substantial milestones in the realm of chronic kidney disease treatment. The year witnessed the company's strategic revisions in its Phase 3 program aimed at expediting the introduction of rilparencel to the U.S. market. Significant financial backing of $140 million was secured to support operational needs through mid-2027. This funding underpins ProKidney's commitment to advancing innovative therapies for patients at high risk of dialysis.

Clinical and Regulatory Advancements

The advancements made in 2024 solidify ProKidney’s reputation as an industry leader in cellular therapies for chronic kidney disease (CKD). Crucial discussions with the U.S. Food and Drug Administration (FDA) confirmed that the accelerated approval pathway for rilparencel is achievable, provided that an acceptable surrogate endpoint, particularly the eGFR slope, is utilized. This pathway opens doors for potential faster access to treatment for patients.

Amid these regulatory efforts, the company is expecting full data from Group 1 of its Phase 2 REGEN-007 study in the upcoming quarters. Interim findings released in June showed promising results, indicating stabilization of kidney function for an impressive duration of 18 months among advanced CKD patients with diabetes, showcasing the therapeutic potential of rilparencel.

Financial Highlights and Strategic Growth

Ending the fourth quarter of 2024, ProKidney reported cash, cash equivalents, and marketable securities totaling $358 million, a solid reserve that supports its ongoing operations and clinical initiatives into 2027. Although research and development expenses rose to $127.7 million in 2024 compared to $106.7 million in 2023, this increase is reflective of the company's aggressive hiring strategy and commitment to enhancing clinical development capabilities.

General and administrative costs also saw a rise to $56.1 million in 2024, a jump driven primarily by cash-based compensation adjustments, reflecting the hiring of skilled professionals to drive research and internal operations forward.

Looking Ahead: The Future of ProKidney

Looking ahead, ProKidney is strategically positioned for a transformative 2025. The anticipated release of complete data from the Phase 2 REGEN-007 study and updates regarding the accelerated approval pathway are expected to be pivotal moments for the company.

Commitment to Innovation

ProKidney’s relentless pursuit of innovation is evident in its well-respected clinical trials like the ongoing Phase 3 REGEN-006 (PROACT 1), which focuses on patients with type 2 diabetes suffering from advanced CKD. This study seeks to assess the efficacy of rilparencel through a minimally invasive approach, with plans to enroll approximately 685 participants.

About ProKidney Corp.

Founded in 2015 after extensive research, ProKidney is dedicated to pioneering cellular therapies for CKD. Its lead product, rilparencel (also known as REACT), is designed to protect kidney function in diabetes patients at significant risk of failure. Backed by the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, ProKidney stands at the forefront of innovation in treating chronic conditions.

Frequently Asked Questions

What is ProKidney's main focus area?

ProKidney primarily focuses on the development of cellular therapies for chronic kidney disease.

How much funding did ProKidney raise in 2024?

In 2024, ProKidney successfully raised $140 million to support its operations and research activities.

What are the key clinical trials being conducted by ProKidney?

ProKidney is currently conducting the Phase 2 REGEN-007 study and the Phase 3 REGEN-006 (PROACT 1) trial.

What was the cash position of ProKidney at the end of 2024?

As of the end of 2024, ProKidney reported $358 million in cash, cash equivalents, and marketable securities.

How does ProKidney plan to use the funds raised?

The funds raised will be utilized to further advance clinical trials, support research initiatives, and expand operational capabilities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

United Bank Secures Crucial $75M Tax Credit for Growth

Updated Category News Views 148

United Bank Receives Significant Tax Credit Allocation United Bank is excited to share that it has been awarded a substantial allocation of $75 million under the New Markets Tax Credit (NMTC) program. This funding, granted by the Department of the Treasury through its affiliated Community Development Entity, UB Community Development, is a testament to the bank's ongoing...

Continue Reading
Exploring Intangible Assets in ASEAN Capital Markets

Updated Category News Views 245

Understanding Intangible Assets in ASEAN Capital Markets Global consulting firm J.S. Held has collaborated with notable organizations to produce an insightful report examining the landscape of intangible assets in ASEAN capital markets. This partnership involves the International Valuation Standards Council (IVSC), the Intellectual Property Office of Singapore (IPOS), and...

Continue Reading
Festival Celebrates Community with Food and Support Services

Updated Category News Views 180

Union Station Homeless Services Teams with Boomtown Brewery Union Station Homeless Services (USHS) collaborates with Boomtown Brewery for a vibrant Summer Sampler Food Festival. This delightful event will showcase not just delicious food but also the spirit of community and cooperation. A Flavorful Afternoon to Remember Taking center stage will be the wide array of...

Continue Reading
Flowable Showcases Cutting-Edge AI Solutions at Gartner Event

Updated Category News Views 260

Flowable Presents Innovative AI Solutions at Gartner Symposium Flowable CEO and CTO to Showcase Responsible AI-Driven Solutions Flowable, a leader in intelligent automation and enterprise transformation, is set to exhibit and present at the renowned Gartner IT Symposium/Xpo 2025 in Barcelona, Spain. This significant gathering of IT professionals will take place from...

Continue Reading
Accounts Receivable Automation Market Set for Major Growth

Updated Category News Views 214

Transforming Financial Management: The Rise of Accounts Receivable Automation As businesses seek operational excellence, the Accounts Receivable (AR) automation market is on a remarkable upswing. It's set to hit USD 3.8 billion by 2033, sporting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2033. This trend signifies a notable change in how companies handle...

Continue Reading